Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma
Ling Xue,Pingfan Wu,Xiaowen Zhao,Xiaojie Jin,Jingjing Wang,Yuxiang Shi,Xiaojing Yang,Yali She,Yaling Li,Changtian Li
DOI: https://doi.org/10.2147/IJGM.S335266
IF: 2.145
2021-10-08
International Journal of General Medicine
Abstract:Ling Xue, 1, 2 Pingfan Wu, 1, 2 Xiaowen Zhao, 1, 2 Xiaojie Jin, 3 Jingjing Wang, 1 Yuxiang Shi, 1 Xiaojing Yang, 1 Yali She, 3 Yaling Li, 1, 3 Changtian Li 1 1 College of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China; 2 Department of Pathology, The 940th Hospital of the Joint Logistic Support of the People's Liberation Army, Lanzhou, 730050, People's Republic of China; 3 Provincial-Level Key Laboratory of Molecular Medicine of Major Diseases and Study on Prevention and Treatment of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, People's Republic of China Correspondence: Yaling Li; Changtian Li College of Basic Medicine, Gansu University of Chinese Medicine, 35 Dingxi Dong Lu, Chengguan District, Lanzhou, 730000, People's Republic of China Tel +86 13919469095 ; +86 1335931598 Email ; Background: Cutaneous melanoma is a highly malignant skin tumor, and most patients have a poor prognosis. In recent years, immunotherapy has assumed an important role in the treatment of advanced cutaneous melanoma, but only a small percentage of patients benefit from immunotherapy. A growing number of studies have demonstrated that the prognosis of patients with cutaneous melanoma is closely related to long non-coding RNA and the tumor immune microenvironment. Methods: We downloaded RNA expression data and immune-related gene lists of cutaneous melanoma patients separately from The Cancer Genome Atlas database and ImmPort website and identified immune-related lncRNAs by co-expression analysis. The prognostic model was constructed by applying least absolute shrinkage and selection operator regression, and all patients were classified into high- and low-risk groups according to the risk score of the model. We evaluated the differences between the two groups in terms of survival outcomes, immune infiltration, pathway enrichment, chemotherapeutic drug sensitivity and immune checkpoint gene expression to verify the impact of lncRNA signature on clinical prognosis and immunotherapy efficacy. Results: By correlation analysis and LASSO regression analysis, we constructed an immune-related lncRNA prognostic model based on five lncRNA: HLA-DQB1-AS1, MIR205HG, RP11-643G5.6, USP30-AS1 and RP11-415F23.4. Based on this model, we plotted Kaplan–Meier survival curves and time-dependent ROC curves and analyzed its ability as an independent prognostic factor for cutaneous melanoma in combination with clinicopathological features. The results showed that these lncRNA signature was an independent prognostic factor of cutaneous melanoma with favorable prognostic ability. Our results also show a higher degree of immune infiltration, higher expression of immune checkpoint-associated genes, and better outcome of immunotherapy in the low-risk group of the lncRNA signature. Conclusion: The 5 immune-related lncRNA signatures constructed in our study can predict the prognosis of cutaneous melanoma and contribute to the selection of immunotherapy. Keywords: melanoma, long non-coding RNA, immune checkpoint, TCGA, GSEA Melanoma, a malignant tumor produced by melanocytes, most commonly occurs to the skin. Melanoma accounts for more than 75% of all deaths from skin tumors due to its high malignancy, susceptibility to metastasis, and lethality. Since 1975, the incidence of melanoma has been increasing worldwide. 1,2 Melanoma has a 5-year survival rate of 98% after surgical treatment, while this percentage drop significantly for advanced or metastatic melanoma. 3 For advanced melanoma, treatment options include chemotherapy, radiation therapy, targeted therapy and immunotherapy. Melanoma is one of the most immunogenic tumors due to its high mutational burden, therefore immunotherapy plays a major role in the treatment of advanced melanoma, and popular immunotherapeutic agents include ipilimumab targeting CTLA-4 and nivolumab targeting PD-1. 4,5 But often only a few patients respond well to immunotherapy. 6 Various factors such as the considerations of the tumor cells themselves and the state of tumor microenvironment (TME) can affect the effectiveness of immunotherapy, tumors with a high degree of immune infiltration, tend to have a better treatment outcome. The TME contains a large number of immune cells, and the crosstalk between tumor and immune cells significantly affects the development of tumor invasion, clinical response and treatment outcome. 7 Since the immune system can detect and destroy tumor cells through immunosurveillance or play a pro-tumor -Abstract Truncated-
medicine, general & internal